ACTRN12606000283572招募中4 期
A phase 4, open-label, multi-centre, observational extension study monitoring the long-term safety and efficacy of adefovir dipivoxil 10mg daily in treatment experienced patients with chronic hepatitis B.
Prof. Meng Ngu, Concord Hospital0 个研究点目标入组 28 人开始时间: 2006年7月5日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Comment: Since this study is an extension study to studies 437/438/480, minimal inclusion/exclusion criteria apply. (The original study included both male and female participants over the age of 18 years). Inclusion:• Participation in and completion of study GS-98-437, GS-98-438 or GS-00-480.• Currently treated with adefovir dipivoxil 10mg once a day.
排除标准
- •Pregnant or breastfeeding females• Known hypersensitivity to adefovir, adefovir dipivoxil, or any of the excipients in adefovir dipivoxil tablets.
研究者
相似试验
招募中
4 期
A study to evaluate the safety and effectiveness of Saroglitazar 4 mg in patients with NAFLD with comorbiditiesCTRI/2023/05/053326Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)
进行中（未招募）
不适用
Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa vaccine in healthy infants.Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b diseases.EUCTR2013-003428-34-Outside-EU/EEAGlaxoSmithKline Biologicals224
进行中（未招募）
不适用
Evaluation of GSK Biologicals’ Boostrix Polio in healthy adults, 10 years after a booster vaccination.Booster immunisation of healthy adults against diphtheria, tetanus, pertussis and poliomyelitis.MedDRA version: 14.0Level: PTClassification code 10043376Term: TetanusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: PTClassification code 10034738Term: PertussisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: PTClassification code 10013023Term: DiphtheriaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: PTClassification code 10036012Term: PoliomyelitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-012219-16-DEGlaxoSmithKline Biologicals300
进行中（未招募）
1 期
This is a non-randomised, open-label which means that patients know they will receive the active medicine. No placebo will be used. The study will examine the effect and safety of Iluvien® in chronic diabetic macular edema patients. Patients would have been treated previously with other available therapies such as laser photo coagulation or a therapy called anti-VEGF or with corticosteroid therapy.Chronic Diabetic Medical EdemaEUCTR2014-003491-23-PTAIBILI – Association for Innovation and Biomedical Research on Light and Image
进行中（未招募）
不适用
A phase IV, randomized, open-label, multi-center study in adults: Evaluation of long-term immunogenicity in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer) in study V48P2E1, 5 years after first booster immunization and Evaluation of booster kinetics in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer), 5 years after first booster immunization. - not availableTBE prophylaxisEUCTR2005-004459-36-DEChiron Behring GmbH & Co KG190